C3L-04014
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 57.59069131
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.390
- E2F_TARGETS+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- G2M_CHECKPOINT+0.300
- MYC_TARGETS_V1+0.250
- SPERMATOGENESIS+0.200
- KRAS_SIGNALING_DN+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.130
- CHOLESTEROL_HOMEOSTASIS+0.120
- MTORC1_SIGNALING+0.120
Top 10 suppressed
- TGF_BETA_SIGNALING-0.320
- ALLOGRAFT_REJECTION-0.280
- IL2_STAT5_SIGNALING-0.280
- TNFA_SIGNALING_VIA_NFKB-0.270
- INFLAMMATORY_RESPONSE-0.260
- KRAS_SIGNALING_UP-0.240
- ANDROGEN_RESPONSE-0.230
- IL6_JAK_STAT3_SIGNALING-0.220
- HEDGEHOG_SIGNALING-0.190
- UV_RESPONSE_DN-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-7139-01A-11R-2045-07 | — | cohortSQ2 | 0.829 |
| 2 | TCGA-DK-A1AE-01A-11R-A13Y-07 | — | — | 0.814 |
| 3 | 20090275.TNBC | — | E | 0.808 |
| 4 | TCGA-B6-A0I1-01A-11R-A21T-07 | — | E | 0.807 |
| 5 | TCGA-QK-A6VB-01A-12R-A34R-07 | — | — | 0.805 |
| 6 | ERR2208894 | — | — | 0.805 |
| 7 | TCGA-NC-A5HD-01A-11R-A26W-07 | — | cohortSQ1 | 0.801 |
| 8 | C3L-02649 | — | cohortMD1 | 0.800 |
| 9 | SRR8942959 | — | — | 0.798 |
| 10 | TCGA-GU-AATQ-01A-11R-A39I-07 | — | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |